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Objectives This study was designed to examine whether a cyclic adenosine monophosphate (cAMP) phosphodiesterase
(PDE), PDE4, is expressed in human atrium and contributes to the control of electrical stability.
Background Atrial fibrillation is accompanied by a profound remodeling of membrane receptors and alterations in cAMP-
dependent regulation of Ca2 handling. Being responsible for cAMP hydrolysis, PDEs are likely to play a role in
this setting. In the rodent heart, PDE4 contributes up to 60% of total cAMP-hydrolytic activity. However, its role
in the human heart remains controversial.
Methods L-type Ca2 current and spontaneous Ca2 release were recorded in isolated human atrial myocytes. Intracellu-
lar cAMP was measured by live cell imaging using a fluorescence resonance energy transfer-based sensor. Con-
tractile force and arrhythmias were recorded in human atrial trabeculae. PDE activity was measured in human
atrial tissue from patients in sinus rhythm and permanent atrial fibrillation.
Results PDE4 is expressed in human atrial myocytes and accounts for approximately 15% of total PDE activity. PDE4D repre-
sents the major PDE4 subtype. PDE4 inhibition increased intracellular cAMP and L-type Ca2 current and dramati-
cally delayed their decay after a brief -adrenergic stimulation. PDE4 inhibition also increased the frequency of spon-
taneous Ca2 release at baseline, as well as the contractile response and the incidence of arrhythmias in human
atrial strips during -adrenergic stimulation. Total PDE activity decreased with age, and the relative PDE4 activity was
lower in patients with permanent atrial fibrillation than in age-matched sinus rhythm controls.
Conclusions PDE4 is critical in controlling cAMP levels and thereby Ca2 influx and release in human atrial muscle,
hence limiting the susceptibility to arrhythmias. (J Am Coll Cardiol 2012;59:2182–90) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.060(
t
nCyclic adenosine monophosphate (cAMP) elevation in
human atrial myocytes (HAMs) leads to a positive chrono-
tropic, inotropic, and lusitropic effect that is primarily
mediated by protein kinase A (PKA)-dependent phosphory-
lation of key proteins, such as L-type Ca2 channels
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June 12, 2012:2182–90 PDE4 in Human Atrium Protects Against Arrhythmiasstimulation of -adrenergic receptors (-ARs) by norepi-
ephrine released from the sympathetic nervous system in
esponse to stress or exercise. -ARs signal primarily
hrough Gs-proteins, resulting in the stimulation of adeny-
lyl cyclases and cAMP synthesis. -AR signaling is rapidly
terminated through several processes, among which cAMP
degradation by cAMP phosphodiesterases (PDEs) plays a prom-
inent role. PDEs comprise a large group of isoenzymes that are
divided into 11 PDE families based on their substrate and
inhibitor specificity and sequence homology (2). Of these, PDE3
nd PDE4 contribute most of the cAMP-hydrolytic activity in
odent cardiomyocytes (3). Although the role of PDE3 in
controlling contractile and electrical activity in human heart
has been studied extensively (4,5), the role of PDE4 has not
been investigated in detail.
The PDE4 family consists of 4 genes (PDE4A, PDE4B,
DE4C, and PDE4D), but only PDE4A, PDE4B, and
DE4D are expressed in the heart (6,7). Here, we demon-
trate that all 3 isoforms are also expressed in isolated
AMs. We demonstrate that PDE4 contributes to cAMP
ydrolysis in human atrium and thereby controls Ca2
influx through LTCCs and thus contractility, both at basal
and during -AR stimulation. PDE4 inhibition in HAMs
increases the frequency of nonpropagating Ca2 release
(Ca2 sparks) and propagating Ca2 release (Ca2 waves),
which is a source of spontaneous membrane depolarization
and arrhythmias. Accordingly, PDE4 inhibition increased
the incidence of arrhythmias during -AR stimulation in
uman atrial tissue. Patients with permanent atrial fibrilla-
ion (AF) were found to have a decreased PDE4 activity as
ompared with patients in sinus rhythm. Thus, this study
emonstrates that PDE4 controls cAMP- and PKA-
ependent signaling in human atrium and protects against
rrhythmias.
ethods
he study conformed to the principles outlined in the
eclaration of Helsinki and was approved by the ethics
ommittees of our institutions. All protocols for obtaining
uman cardiac tissue were approved by the ethics com-
ittees, and informed consent was obtained before car-
iac surgery. Patient characteristics; drugs and methods
sed for isolation, culture, and infection of HAMs;
-type Ca2 and transient inward current measurements;
ive cell imaging of intracellular cAMP; confocal Ca2
imaging; preparation of protein extracts; PDE immuno-
precipitation; immunocytochemistry; PDE activity assay;
mechanoelectrical measurements; and data analysis and
statistics are detailed in the supplemental methods sec-
tion in the Online Appendix.
Results
Expression and localization of PDE4 in human right
atrium. The 4 major cardiac cAMP PDEs expressed in
rodent heart (3,6), PDE1, PDE2, PDE3, and PDE4, werealso found to be expressed in
human atrium (Fig. 1A). Of par-
ticular interest is the presence of
PDE4, which accounts for ap-
proximately 15% of total cAMP-
hydrolytic activity. Immunopre-
cipitation assays using PDE4
subtype selective antibodies re-
vealed that the 3 cardiac PDE4
subtypes previously identified in
rats (6), PDE4A, PDE4B, and
PDE4D, are also expressed in
human atrium, with PDE4D
contributing the largest amount
(Fig. 1B). PDE4C message is
not found in expressed sequence
tags (EST) databases of mouse,
rat, and human heart, and the
amount of PDE activity immu-
noprecipitated in preliminary ex-
periments with anti-PDE4C an-
tibodies was negligible compared
with that of PDE4A, PDE4B,
and PDE4D (data not shown).
For these reasons, PDE4C was
not investigated further. Western
blot analysis revealed one major
immunoreactive band for PDE4D
in human atrium whose migra-
tion is consistent with that of
PDE4D3, PDE4D8, or PDE4D9 (inset in Fig. 1B).
Specific expression of PDE4 in HAMs also was demon-
strated by immunostaining. PDE4 enzymes were detected
at the Z-line of atrial myocytes, colocalized with the
sarcomere-associated protein -actinin (Fig. 1C).
PDE4 controls basal intracellular cAMP concentration
in HAMs. Intracellular cyclic adenosine monophosphate
([cAMP]i) was measured in HAMs by live cell imaging
using the fluorescence resonance energy transfer-based
cAMP sensor Epac2-camps (8). Application of the -AR
gonist isoprenaline (Iso) (100 nM) during a 15-s pulse
roduced a rapid and transient change in the cyan fluores-
ent protein and yellow fluorescent protein fluorescence
Fig. 2A), leading to a transient increase of the cyan
uorescent protein-to-yellow fluorescent protein ratio (Fig. 2B),
eflecting an increase in [cAMP]i. Application of the PDE4
nhibitor Ro 20-1724 (Ro; 10 M) produced a small but
ignificant increase in basal [cAMP]i (Figs. 2C and 2E) that
as approximately 50% smaller than that induced by cilosta-
ide (1 M), a PDE3 inhibitor (Figs. 2D and 2E). When
the 2 PDEs were blocked simultaneously (Ro plus cilosta-
mide), [cAMP]i increased further (Figs. 2C and 2D) to
reach approximately 50% of the Iso response (Fig. 2E).
These results indicate that PDE3 and PDE4 jointly control
Abbreviations
and Acronyms
AF  atrial fibrillation
-AR  -adrenergic
receptor
cAMP  cyclic adenosine
monophosphate
[cAMP]i  intracellular
cyclic adenosine
monophosphate
Ca2 sparks 
nonpropagating Ca2
release
Ca2 waves  propagating
Ca2 release
HAM  human atrial
myocyte
HF  heart failure
ICa,L  L-type Ca
2 channel
current
Iso  isoprenaline
LTCC  L-type Ca2
channel
PDE  phosphodiesterase
PKA  protein kinase A
Ro  Ro 20-1724
RyR2  ryanodine receptor
SR  sinus rhythmbasal cAMP levels in HAMs.
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PDE4 in Human Atrium Protects Against Arrhythmias June 12, 2012:2182–90PDE4 modulates cAMP and L-type Ca2 current responses
to -AR stimulation in HAMs. To determine whether the
control of basal [cAMP]i by PDE4 translates into biological
functions, we examined whether PDE4 modulates the
L-type Ca2 current (ICa,L). As shown in Supplemental
Figure 1A, Ro increased basal ICa,L in a concentration-
ependent manner and the effect was fully reversible. Next,
e examined whether PDE4 controls the response of ICa,L
and [cAMP]i to Iso in HAMs. Figure 3 shows the average
response of isolated HAMs to a brief -AR stimulation
with Iso (15 s, 100 nM). [cAMP]i (Fig. 3A) and ICa,L (Fig. 3C)
ncreased to reach a maximum at approximately 60 and 80 s,
espectively, and then returned progressively to basal levels
ith a similar time course (Figs. 3B and 3D). Because the
ecay of the fluorescence ratio reflects hydrolysis of cAMP
9), the contribution of PDE4 to this process was examined
y repeating the Iso application in the presence of Ro.
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Figure 1 Phosphodiesterase Families Expressed in Human Atriu
(A) Detergent extracts prepared from human atrium were subjected to phosphodie
tors using 1 M cyclic adenosine monophosphate as substrate. Family-specific PD
cetine (PDE1), 0.1 M Bay60-7550 (PDE2), 10 M cilostamide (PDE3), or 10 M
prepared from human atrium were subjected to immunoprecipitations (IP) using PD
corrected for the amount of protein used as IP input is reported. (Inset) sodium d
types expressed in human atrium. Detergent extracts prepared from human atrium
normal immunoglobulin G (IgG) as a control. Shown is the PDE4D expression in ce
and the PDE4D species recovered in the IP pellets (right) by Western blotting with
cytes. Isolated human atrial myocytes were stained with anti-PAN-PDE4 antibody (i
images (merge) and magnification of the area within the white rectangle revealedDE4 inhibition dramatically slowed down the decay phase mf [cAMP]i (Fig. 3A) by increasing the time for half
ecovery by approximately 2-fold (Fig. 3B). The prolonga-
ion of the [cAMP]i response to Iso resulted in a similar
2-fold prolongation of the ICa,L response (Figs. 3C and 3D)
ecause of a prolonged PKA phosphorylation of LTCCs.
herefore, PDE4 plays a crucial role in controlling cAMP
evels and ICa,L on -AR stimulation in HAMs. PDE3
ontributes more than PDE4 to the recovery of the -AR
response, because cilostamide prolonged the decay phase of
[cAMP]i and ICa,L approximately 2.5-fold and 3-fold,
espectively (Fig. 3).
DE4 inhibition increases spontaneous Ca2 release
rom the sarcoplasmic reticulum. Local Ca2 sparks and
Ca2 waves were recorded in isolated HAMs. Continuous
xposure of a HAM to 10 M Ro for 15 min increased the
frequency of Ca2 sparks in a reversible manner (Fig. 4A).
n HAMs with the membrane potential clamped at 80
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250 kDa
e (PDE) activity assays in the absence or presence of PDE family-selective inhibi-
vities were defined as the portion of total PDE activity inhibited by 20 M vinpo-
m (PDE4). (B) PDE4 subtypes expressed in human atrium. Detergent extracts
btype-selective antibodies. The amount of PDE activity recovered in the IP pellets
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) migration of PDE4 sub-
subjected to coimmunoprecipitation assays using PDE4D-selective antibodies or
acts that had been depleted with either control IgG or PDE4D antibodies (left)
D-selective antibodies. (C) Distribution of PDE4 in isolated human atrial myo-
nonspecific anti-PDE4 antibody) and with anti--actinin antibody. Superimposed
rlapping distribution of PDE4 with -actinin.M
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June 12, 2012:2182–90 PDE4 in Human Atrium Protects Against Arrhythmias3-fold by PDE4 inhibition (Fig. 4B), whereas neither Ca2
spark amplitude nor the time constant for decay were
modified (data not shown). Ro also increased the frequency
of spontaneous Ca2 waves and inward Na/Ca2-
xchange current (Fig. 4C). On average, PDE4 inhibition
ncreased the spontaneous Ca2 wave frequency approxi-
ately 3-fold at 80 mV (Fig. 4D), but the effect was
ot significant when the holding potential was increased
o 50 mV, possibly because the wave frequency already
as near maximum in the absence of Ro. These results
ndicate that PDE4 activity is necessary to prevent
pontaneous Ca2 release from the sarcoplasmic reticu-
lum, which is a source of spontaneous membrane depo-
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Figure 2 Regulation of Basal Cyclic Adenosine Monophosphate
(A) Real-time measurement of cyclic adenosine monophosphate (cAMP) levels in r
were infected with the Epac2-camps adenovirus. The graph shows the time course
response to a brief application of isoprenaline (Iso; 100 nM, 15 seconds). Transie
energy transfer between CFP (excited at 440  20 nm) and YFP visualized by a si
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were obtained at the times indicated by the corresponding letters in the bottom gr
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during -AR stimulation. Mechanoelectrical measure-
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he right atrium of 9 patients. PDE4 inhibition with 10 M
o had no effect on the force of contraction under basal
onditions (Online Fig. 2A). However, Ro increased the
ositive inotropic effect of cilostamide (Online Figs. 2A and
B) or of a submaximal -AR stimulation of 10 nM Iso
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urred in the combined presence of PDE inhibitors and Iso
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PDE4 in Human Atrium Protects Against Arrhythmias June 12, 2012:2182–90responsible for potential proarrhythmic effects of PDE
inhibition. Selective 1-AR stimulation with increasing
concentrations of norepinephrine in the presence of a
2-AR antagonist (ICI 118.551, 50 nM) increased the force
of contraction (Fig. 5A), and spontaneous, nontriggered
contractions were observed in less than 20% of fibers for
norepinephrine concentrations of more than 3 M (Fig. 5C).
However, when PDE4 was blocked by rolipram (100 nM),
these spontaneous contractions were observed at lower
norepinephrine concentrations and were approximately 2-fold
more frequent (40%) at higher concentrations (Figs. 5B and 5C).
PDE3 inhibition with milrinone (1 M) had a comparable
effect (Fig. 5C). In contrast, no spontaneous contractions
were observed on 2-AR stimulation with epinephrine
n the presence of the 1-AR antagonist CGP207.12A
(300 nM), even during PDE3 inhibition (Fig. 5D). However,
inhibition of PDE4 had a dramatic effect, causing spontaneous
contractions to occur in up to 40% of the trabeculae at the
highest epinephrine concentrations (Fig. 5D).
AF is linked to a decrease in PDE4 activity. Because
PDE4 seems to be critical in controlling [cAMP]i, ICa,L,
sarcoplasmic reticulum Ca2 release, and contraction in the
human atrium and its inhibition leads to atrial arrhythmias,
we tested whether a change in PDE4 activity might take
place during AF. Total PDE and PDE4 activity was
measured in right atrial tissues from 18 patients in sinus
Figure 3 PDE Regulation of the -AR Response
Average time course of the changes of (A) CFP-to-YFP ratio and (B) ICa,L amplitude
M) or Cil (1 M) were added to the Iso solution and in the washout solution to in
OFF) of the (C) fluorescence resonance energy transfer ratio and (D) ICa,L amplitud
and patients (p). Other abbreviations as in Figures 1 and 2.rhythm (SR) and 7 patients with permanent AF. Elevenpatients with heart failure (HF) were also included in this
study because HF patients are at substantially increased risk
of having AF (10). Mean values for total PDE were smaller
in patients with HF and AF than those in SR (Fig. 6A), but
the difference (approximately a 25% decrease) approached
statistical significance (p 0.059) only when comparing SR
and AF patients. More importantly, PDE4 activity de-
creased by almost 50% (p  0.029) in AF (17.1  3.9
pmol/min per mg) as compared with SR patients (32.9 
3.9 pmol/min per mg). Although the age of the patients was
not significantly different in the 3 groups (p  0.071 for AF
vs. SR; p  0.136 for HF vs. SR), patients in the SR group
were on average younger (66.8  3.0 years) than in the HF
group (73.2  2.0 years) or AF group (76.4  2.3 years).
This raised the possibility that the changes in PDE
activities might be the result of aging, rather than of the
cardiac disease. Indeed, when total PDE activity for SR
patients was plotted against patient age, a linear regres-
sion analysis showed a significant reduction with age (p 
0.0054) (Fig. 6B). Thus, to match the average age of the
HF and AF groups, only the SR patients who were 59
years of age or older (mean age: 72.0  2.2 years, n  14)
were included in subsequent analysis. The contribution of
PDE4 to total PDE activity was found to be reduced in
HF and AF patients as compared with this SR group, but
the difference (approximately a 25% decrease) approached
g a brief -AR stimulation with Iso (100 nM, 15 seconds) alone or when Ro (10
DE4 and PDE3, respectively. Mean values of the time for 50% recovery (T1/2
symbols and bar graphs indicate the mean  SEM of the number of cells (c)durin
hibit P
e. Thestatistical significance (p  0.057) only when comparing
L
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June 12, 2012:2182–90 PDE4 in Human Atrium Protects Against Arrhythmiasage-matched SR and AF patients (Fig. 6C). These
findings support the hypothesis that a decrease in PDE4
activity may be associated with the development of AF.
Discussion
Our study demonstrates that PDE4 is expressed in human
atrium as well as in isolated HAMs, with PDE4D being the
major isoform. Despite the fact that its activity is rather
modest (approximately 15% of total PDE activity), PDE4 is
central in controlling [cAMP]i, Ca
2 influx through
TCCs, spontaneous Ca2 release from the sarcoplasmic
eticulum, and contractility. PDE4 seems particularly im-
ortant in regulating the -AR response of human atrial
muscle, because inhibition of PDE4 leads to an increase in
the positive inotropic effect of a -AR stimulation and to a
ramatic prolongation of the rise in [cAMP]i and ICa,L
amplitude. PDE4 inhibition also increased the propensity of
atrial arrhythmias during either 1-AR or 2-AR stimula-
tion. Because the relative contribution of PDE4 to the total
cAMP hydrolytic activity decreased in patients with perma-
nent AF, we propose that PDE4 serves a protective role
Figure 4 PDE4 Inhibition Increases Spontaneous Sarcoplasmic
(A) Confocal image of a human atrial myocyte with 3 regions of interest (ROIs)
(Ca2 waves) were detected 2, 7, and 12 min after exposure to 10 M Ro and
17 min of wash. (B) Average effect (mean  SEM) of Ro on the spark frequen
(C) Simultaneous recordings of the global Ca2 signal (upper trace) and the w
duration recorded before (control) or 10 to 12 min after exposure of the myocy
on the spontaneous Ca2 wave frequency in 16 myocytes from 11 patients claagainst arrhythmias in human atrial muscle.The PDE4 family is encoded by 4 genes (PDE4A,
PDE4B, PDE4C, and PDE4D), but only PDE4A, PDE4B,
and PDE4D are expressed in cardiac tissue (6,7). So far,
most of our knowledge in heart tissue concerns the PDE4D
gene (11), and long variants of this gene expressed in heart
include the isoforms PDE4D3, PDE4D5, PDE4D8, and
PDE4D9 (12). PDE4D5, PDE4D8, and PDE4D9 were
shown to interact differentially with 1-AR and 2-AR
subtypes in neonatal cardiac myocytes, either directly or by
binding to -arrestin (13–15). PDE4D3 was found in
macromolecular signaling complexes regulating 2 major
players of excitation-contraction coupling in rodent heart:
the slow delayed rectifier K current (16) and the ryanodine
eceptor RyR2 (17). Interestingly, inhibition of PDE4D
eads to an increased PKA activation of the slow delayed
ectifier K current (16), which can contribute to AF (18).
Here we found that PDE4D was the dominant member of
the PDE4 family expressed in human atrium. Pharmaco-
logical inhibition of PDE4 (which includes inhibition of
PDE4D) increased Ca2 spark frequency in HAMs and led
o the initiation and propagation of Ca2 waves (Fig. 4).
These Ca2 waves in turn generated a transient inward
ulum Ca2 Release
nonpropagating Ca2 release (Ca2 sparks) and propagating Ca2 release
in after washout. No sparks were detected before exposure to Ro or after
80 mV in 15 myocytes from 10 patients. *p  0.05 versus control.
embrane current (lower trace). The figure shows consecutive traces of 28 s
10 M Ro. The Ca2 signal is in a.u. (D) Average effect (mean  SEM) of Ro
at 80 or 50 mV. Other abbreviations as in Figures 1 and 2.Retic
where
12 m
cy at 
hole m
te to
mpedNa/Ca2-exchange current as a result of elimination of
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PDE4 in Human Atrium Protects Against Arrhythmias June 12, 2012:2182–90cytosolic Ca2 via the Na/Ca2 exchanger (Fig. 4), which
an give rise to delayed after-depolarizations (19). Impor-
antly, Ca2 spark frequency is also increased in HAMs
rom AF patients (20 –22), coinciding with an increased
hosphorylation of the RyR2 at Ser2808 in right atrial
samples from patients with AF (21–23), and an increased
open probability of RyR2 resulting from PKA hyper-
phosphorylation has been reported in an AF animal
model (23). Moreover, mice deficient in the PDE4D gene
have an increased sensitivity to exercise-induced ventric-
ular arrhythmias resulting from PKA hyperphosphoryla-
tion of RyR2 and abnormal Ca2 release as a result of
calstabin dissociation from the channel (17). Thus, there is
strong evidence to suggest that PDE4 inhibition may lead to
Figure 5
PDE4 Inhibition Increases Frequency
of Arrhythmias After 1-AR and 2-AR
Stimulation in Human Atrial Myocardium
Human atrial muscle strip preparations were stimulated at 1 Hz and were
exposed to cumulative concentrations of norepinephrine (NE) in the presence
of ICI 118.551 (50 nM) or epinephrine (EPI) in the presence of CGP207.12A
(300 nM) to stimulate selectively 1-AR or 2-ARs, respectively. Experiments
were carried out in the absence (control) or presence of rolipram (Roli;
100 nM) or milrinone (Milri; 1 M). Representative traces of NE in (A) the
absence and (B) the presence of rolipram, respectively. The top traces
indicate original contractions recorded during the gray shaded areas in the
bottom graphs. Black dots indicate the time points of electrical stimula-
tion. Cumulative frequency of arrhythmias (C) after 1-AR and (D) 2-AR
stimulation in the absence (Con; n  26 for 1-AR and n  23 for 2-AR
stimulation) and presence of rolipram (Roli; n  20/15) or Milrinone (Milri;
n  11/11), respectively. *p  0.05 and **p 0.01 versus control and
†p  0.05 versus milrinone (Fisher exact test, respectively). Abbreviations
as in Figure 2.abnormal Ca2 release in human atrial cardiomyocytes via PyR2 hyperphosphorylation. Accordingly, PDE4 inhibition in
uman atrial trabeculae increased the incidence of arrhythmias
uring -AR stimulation (Fig. 5).
PDE4 inhibition increased both basal ICa,L (Online Fig. 1) and
spontaneous Ca2 sparks (Fig. 4) in HAMs. Yet, live cell
maging showed a limited increase in basal [cAMP]i on
Figure 6 Measurements of Total PDE and PDE4 Activity in
Human Atrial Tissues
(A) Individual and mean values for total PDE activity measured in right atrial tis-
sues obtained from patients with sinus rhythm (SR), heart failure (HF; i.e., patients
with ejection fraction  60%), or permanent atrial fibrillation (AF). (B) Plot of the
total PDE activity as a function of the patient’s age. A linear regression analysis is
shown. (C) PDE4 activity relative to total in age-matched patients in the 3 groups:
SR, HF, and AF. For statistical evaluation, an unpaired Student t test was used in
(A) and (C), and an F test was used in (B) to tests if the slope was significantly
different from 0. Abbreviations as in Figure 1.DE4 inhibition (Fig. 2). By comparison, the increase in
4
s
c
R
t
o
d
n
H
I
p
g
a
p
p
e
r
Y
h
o
i
p
c
t
t
t
H
i
p
i
1
1
1
1
1
1
1
1
2189JACC Vol. 59, No. 24, 2012 Molina et al.
June 12, 2012:2182–90 PDE4 in Human Atrium Protects Against Arrhythmias[cAMP]i was twice as large when PDE3 was inhibited and
times larger when both PDE3 and PDE4 were blocked
imultaneously. Thus, PDE4 inhibition alone may lead to
AMP rise in microdomains close to the LTCCs and the
yR2 that are either too small or not readily accessible to
he cAMP probe.
Although our study demonstrates that an acute inhibition
f PDE4 increases the activity of LTCCs, the observed
ecrease in PDE4 activity in AF patients is not accompa-
ied by a commensurate increase in ICa,L amplitude in
AMs from AF patients. On the contrary, reductions in
Ca,L have been observed consistently in atrial myocytes
from patients with permanent AF (24,25) or from pa-
tients in SR with a high risk of AF (26) (for a review, see
ref 27). A possible explanation for this is that stimulation
of ICa,L by PDE4 inhibition is the result of PKA
hosphorylation of functional LTCCs, whereas it is
enerally agreed (25) that the reduction of ICa,L in AF is
the result of downregulation of the messenger ribonucleic
acid encoding the Cav1.2 -subunit, causing a reduction
in the number of functional channels (27).
Clinical implications. The incidence and prevalence of AF
increases progressively with age, and approximately 50% of
patients with AF are 75 years of age or older (28). Advanced
age is also a potent risk factor for stroke in patients with AF,
and the proportion of strokes attributable to AF increases
exponentially with age (28). Interestingly, an association
between PDE4D and cardioembolic stroke was reported by
the investigators of the Icelandic deCODE study
(deCODE Genetics, Reykjavik, Iceland) (29). Although
the so-called causative mutation has not been identified,
single nucleotide polymorphisms in the PDE4D region
re associated with ischemic stroke in many different
opulations (30). Although none of the single nucleotide
olymorphisms identified affects the catalytic site of the
nzyme, they are associated with a reduced messenger
ibonucleic acid level for different PDE4D isoforms (29).
et, to our surprise, none of the genetic studies published
ave considered the atrium as a possible target for the
bserved reduction in PDE4D expression. Because a rise
n cAMP in vascular and inflammatory cells or in
latelets would lead to vasorelaxation or would inhibit
ell growth, proliferation, migration, neointima forma-
ion, inflammation, and platelet aggregation, it is unlikely
hat a reduction in PDE4D expression in one of these cell
ypes would increase the risk for cardioembolic stroke.
ere, we demonstrate that PDE4D is the major PDE4
soform expressed in HAMs. Hence, our study suggests a
ossible link between PDE4D and cardiogenic stroke that
nvolves abnormal intracellular Ca2 handling in atrial
myocytes that predisposes individuals to AF.
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